Treatment of pemphigus vulgaris with cyclosporine

S. Veraldi, M. Bocor, G. Sarchi, R. Caputo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Eight patients (two males and six females), between 35 and 67 years of age (mean age 52.7 years), with pemphigus vulgaris resistant to corticosteroids and azathioprine or in whom such treatments had provoked severe side-effects, were treated with cyclosporine. The drug was administered at a starting dosage ranging between 3 and 5 mg/kg per day. This dosage was gradually reduced to the minimum effective dosage ranging between 2 and 5 mg/kg per day. In all patients prednisone was also used. Complete remission was observed in five patients, partial remission in one and no response in two. Side-effects and laboratory abnormalities were mild and transitory: in only one patient with severe gingival hyperplasia was it necessary to reduce the dosage of cyclosporine. This drug can be used, in combination with prednisone, in patients with pemphigus vulgaris who are resistant to traditional treatments or in whom such treatments give rise to severe side-effects. Furthermore, cyclosporine allows a reduction of the dosage of prednisone (in our study by about one-third) and therefore, theoretically, the number and severity of side-effects caused by prednisone itself.

Original languageEnglish
Pages (from-to)119-122
Number of pages4
JournalJournal of Dermatological Treatment
Volume8
Issue number2
Publication statusPublished - Jun 1997

Fingerprint

Pemphigus
Cyclosporine
Prednisone
Gingival Hyperplasia
Therapeutics
Azathioprine
Pharmaceutical Preparations
Adrenal Cortex Hormones

Keywords

  • Cyclosporine
  • Pemphigus vulgaris

ASJC Scopus subject areas

  • Dermatology

Cite this

Veraldi, S., Bocor, M., Sarchi, G., & Caputo, R. (1997). Treatment of pemphigus vulgaris with cyclosporine. Journal of Dermatological Treatment, 8(2), 119-122.

Treatment of pemphigus vulgaris with cyclosporine. / Veraldi, S.; Bocor, M.; Sarchi, G.; Caputo, R.

In: Journal of Dermatological Treatment, Vol. 8, No. 2, 06.1997, p. 119-122.

Research output: Contribution to journalArticle

Veraldi, S, Bocor, M, Sarchi, G & Caputo, R 1997, 'Treatment of pemphigus vulgaris with cyclosporine', Journal of Dermatological Treatment, vol. 8, no. 2, pp. 119-122.
Veraldi, S. ; Bocor, M. ; Sarchi, G. ; Caputo, R. / Treatment of pemphigus vulgaris with cyclosporine. In: Journal of Dermatological Treatment. 1997 ; Vol. 8, No. 2. pp. 119-122.
@article{f378779cbda8464e948da53263448650,
title = "Treatment of pemphigus vulgaris with cyclosporine",
abstract = "Eight patients (two males and six females), between 35 and 67 years of age (mean age 52.7 years), with pemphigus vulgaris resistant to corticosteroids and azathioprine or in whom such treatments had provoked severe side-effects, were treated with cyclosporine. The drug was administered at a starting dosage ranging between 3 and 5 mg/kg per day. This dosage was gradually reduced to the minimum effective dosage ranging between 2 and 5 mg/kg per day. In all patients prednisone was also used. Complete remission was observed in five patients, partial remission in one and no response in two. Side-effects and laboratory abnormalities were mild and transitory: in only one patient with severe gingival hyperplasia was it necessary to reduce the dosage of cyclosporine. This drug can be used, in combination with prednisone, in patients with pemphigus vulgaris who are resistant to traditional treatments or in whom such treatments give rise to severe side-effects. Furthermore, cyclosporine allows a reduction of the dosage of prednisone (in our study by about one-third) and therefore, theoretically, the number and severity of side-effects caused by prednisone itself.",
keywords = "Cyclosporine, Pemphigus vulgaris",
author = "S. Veraldi and M. Bocor and G. Sarchi and R. Caputo",
year = "1997",
month = "6",
language = "English",
volume = "8",
pages = "119--122",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Treatment of pemphigus vulgaris with cyclosporine

AU - Veraldi, S.

AU - Bocor, M.

AU - Sarchi, G.

AU - Caputo, R.

PY - 1997/6

Y1 - 1997/6

N2 - Eight patients (two males and six females), between 35 and 67 years of age (mean age 52.7 years), with pemphigus vulgaris resistant to corticosteroids and azathioprine or in whom such treatments had provoked severe side-effects, were treated with cyclosporine. The drug was administered at a starting dosage ranging between 3 and 5 mg/kg per day. This dosage was gradually reduced to the minimum effective dosage ranging between 2 and 5 mg/kg per day. In all patients prednisone was also used. Complete remission was observed in five patients, partial remission in one and no response in two. Side-effects and laboratory abnormalities were mild and transitory: in only one patient with severe gingival hyperplasia was it necessary to reduce the dosage of cyclosporine. This drug can be used, in combination with prednisone, in patients with pemphigus vulgaris who are resistant to traditional treatments or in whom such treatments give rise to severe side-effects. Furthermore, cyclosporine allows a reduction of the dosage of prednisone (in our study by about one-third) and therefore, theoretically, the number and severity of side-effects caused by prednisone itself.

AB - Eight patients (two males and six females), between 35 and 67 years of age (mean age 52.7 years), with pemphigus vulgaris resistant to corticosteroids and azathioprine or in whom such treatments had provoked severe side-effects, were treated with cyclosporine. The drug was administered at a starting dosage ranging between 3 and 5 mg/kg per day. This dosage was gradually reduced to the minimum effective dosage ranging between 2 and 5 mg/kg per day. In all patients prednisone was also used. Complete remission was observed in five patients, partial remission in one and no response in two. Side-effects and laboratory abnormalities were mild and transitory: in only one patient with severe gingival hyperplasia was it necessary to reduce the dosage of cyclosporine. This drug can be used, in combination with prednisone, in patients with pemphigus vulgaris who are resistant to traditional treatments or in whom such treatments give rise to severe side-effects. Furthermore, cyclosporine allows a reduction of the dosage of prednisone (in our study by about one-third) and therefore, theoretically, the number and severity of side-effects caused by prednisone itself.

KW - Cyclosporine

KW - Pemphigus vulgaris

UR - http://www.scopus.com/inward/record.url?scp=0030851577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030851577&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030851577

VL - 8

SP - 119

EP - 122

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 2

ER -